Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: George Sepetjian who wrote (541)	12/23/1997 12:49:00 AM
From: Larry Liebman	Respond to of 3202

I've been avoiding the day-to-day market as the biotech bear continues its rounds...I did notice the mention that PFE might not renew its subscription to the INCY database and the consternation that rumor(or fact) appeared to play with the valuation...I went over to the INCY site..In '97 the company signed-on/or expanded relationships with: Rhone-Poulenc, Monsanto, Organon, Glaxo, Pharmacia, Bristol-Myers, Smithkline Beecham, Genentech, etc. This excludes the "hardware" deals with the high-throughput people, the diagnostic collaborations, etc...While the PFE rumor may play-out, it appears that INCY is not a one-trick pony...